Quantcast

Latest CancerVax Stories

2010-08-10 07:00:00

SAN DIEGO, Aug. 10 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the follow-on Phase 2 grant award from the National Cancer Institute under the Small Business Technology Transfer Program (STTR). The grant is in the amount of $1,100,000 over the next two years subject to...

2010-08-09 10:10:00

GAITHERSBURG, Md., Aug. 9 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical...

2010-06-29 07:30:00

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating the potency of new product candidates based on the Company's proprietary BiTE® antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells. Results published in PNAS characterize new BiTE antibodies...

2010-06-15 15:47:07

Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research. "Our results provide preclinical evidence for the rational combination of BRAF-targeted therapy and immunotherapy in the treatment of this most dangerous type of skin cancer," said lead researcher Jennifer A....

2010-06-07 14:28:00

BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT") (OTC Bulletin Board: NWBO), developer of the DCVax® personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group. As part of an in-depth review of the history and competitive landscape of what he calls the "cancer vaccine revolution," Dr. Malik concludes that "NWBT has...

2010-06-07 08:00:00

BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors. MT110 is designed to direct a patient's T cells, the immune system's most potent killer cells, against cancer cells that...

2010-05-21 06:45:00

BETHESDA, Md., May 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences. Blinatumomab (MT103), the Company's lead product candidate, will be the subject of two oral presentations at the 15th Annual Congress of the...

2010-05-05 06:30:00

BETHESDA, Md., May 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2010. "With the proceeds from our recent financing, we are well-positioned to conduct the planned European pivotal study of blinatumomab in patients with acute lymphoblastic leukemia and other studies...

2010-05-05 06:00:00

INGELHEIM, Germany and BETHESDA, Md., May 5 /PRNewswire-FirstCall/ -- Boehringer Ingelheim and Micromet, Inc. (Nasdaq: MITI) announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma. Despite recent advances in the treatment of multiple myeloma, the disease remains largely incurable. While the majority of patients initially respond to treatment, almost all of...

2010-04-28 01:59:00

LELYSTAD and 'S-HERTOGENBOSCH, The Netherlands, April 28, 2010 /PRNewswire/ -- Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo. "Pepscan has...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related